Mika has raised $12.5M in total across 3 funding rounds.
Mika's investors include Ananda Impact Ventures, Plug & Play Ventures.
Mika refers to the AI-powered digital health platform developed by Fosanis GmbH, a Berlin-based healthcare software company focused on oncology.[1][2] Mika is an app-based digital therapeutic (DTx) that supports cancer patients through daily symptom monitoring via electronic patient-reported outcomes (ePROs), AI-driven personalized coaching, and evidence-based content like nutritional tips, exercise routines, and mindfulness training.[1][2] It serves cancer patients globally, helping them manage symptoms such as depression, anxiety, and fatigue, while enabling active participation in treatment to improve quality of life; the platform has reached over 100,000 users and secured $10.6M in funding.[1][4]
Clinically validated and approved as Germany's first DiGA (digital health application) for all cancer patients in 2021, Mika combines machine learning with partnerships from institutions like University of Leipzig Medical Center and Charité Berlin.[1] In June 2025, its assets were acquired by Outcomes4Me Germany GmbH, accelerating global expansion and integration into a broader AI-driven cancer care ecosystem.[4]
Founded in 2017 by Dr. Gandolf Finke and Dr. Jan Simon Raue, Fosanis GmbH launched Mika to empower cancer patients using digital tools, born from collaborations with top oncological research centers.[1] The idea emerged from a need to address gaps in patient support during therapy, leveraging AI for continuous monitoring and personalized interventions—early milestones included clinical trials proving efficacy in symptom reduction.[1][2][4]
Pivotal traction came with 2021 DiGA approval, making Mika the only such app for all cancer patients in Germany, followed by serving over 100,000 users and $10.6M funding.[1][4] The 2025 acquisition by Outcomes4Me marked a new chapter, blending Mika's European regulatory strengths (MDR IIa-certified) with U.S.-based scalability.[4]
Mika rides the wave of digital therapeutics (DTx) and AI in oncology, addressing rising cancer prevalence amid aging populations and demand for patient-centered care.[1][2][4] Timing aligns with regulatory shifts like Germany's DiGA fast-track and EU MDR standards, plus post-pandemic telehealth growth, positioning it amid market forces favoring scalable, evidence-based apps over traditional clinic visits.[1][4]
It influences the ecosystem by generating proprietary datasets for better outcomes research and setting benchmarks for AI ethics in health—its acquisition by Outcomes4Me amplifies global impact, bridging U.S. clinical guidelines with European infrastructure to standardize digital oncology support.[4]
Mika's trajectory points to deeper integration within Outcomes4Me's $21M-funded platform, targeting expanded AI features like predictive analytics and multi-language support for 280,000+ patients.[4] Trends like generative AI for hyper-personalized care and value-based reimbursement will propel growth, potentially evolving its influence from regional pioneer to global DTx leader in oncology.
This positions Mika as a cornerstone in democratizing cancer management, transforming patient empowerment from app-based aid to ecosystem-wide standard.
Mika has raised $12.5M across 3 funding rounds. Most recently, it raised $11.0M Series A in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2022 | $11.0M Series A | Ananda Impact Ventures | |
| Feb 1, 2013 | $1.0M Series A | Plug & Play Ventures | |
| May 1, 2012 | $500K Seed | Plug & Play Ventures |
